SOURCE: Industrial Info Resources

Industrial Info Resources

August 25, 2010 05:10 ET

Alexion Covers Biomanufacturing Bets With Production Start at New Rhode Island Plant, an Industrial Info News Alert

SUGAR LAND, TX--(Marketwire - August 25, 2010) -  Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- Alexion Pharmaceuticals (NASDAQ:ALXN) (Cheshire, Connecticut) can breathe a small sigh of relief as the company's new manufacturing plant in Smithfield, Rhode Island has received coveted Food and Drug Administration (FDA) approval. Rather than repeat the Genzyme debacle following that company's problems with its Allston, Massachusetts, plant, Alexion wanted to ensure it would not be caught with only a single-source production point for commercial supply of its first product, Soliris (eculizumab).

For details, view the entire article by subscribing to Industrial Info's Premium Industry News at, or browse other breaking industrial news stories at

Industrial Info Resources (IIR) is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. IIR's quality-assurance philosophy, the Living Forward Reporting Principle™, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. For more information send inquiries to or visit us at

Follow us on: Facebook - Twitter - LinkedIn - Vimeo

Contact Information

  • Contact:
    Joe Govreau